// App-Quantinova.ai

BSH2020‐PO‐160 : Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower‐risk myelodysplastic syndromes enrolled in the MEDALIST trial

Researchers

Presenter

  • G. J. Mufti

Principal Investigators

  • P. Vyas

  • G. Garcia-Manero

  • R. Buckstein

  • V. Santini

  • M. Dez-Campelo

  • C. Finelli

  • O. Ilhan

  • M. A. Sekeres

  • R. S. Komrokji

  • A. M. Zeidan

  • A. Verma

  • D. R. Dunshee

  • A. Laadem

  • P. G. Linde

  • A. F. List

  • P. Fenaux

  • U. Platzbecker

Medical Centers

  • Department of Haemato‐Oncology, King's College London, London

  • Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • MDS Unit, Azienda Ospedaliero Universitaria

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca,Salamanca,Espagne

  • Department of Oncology and Hematology, S. Orsola‐Malpighi University Hospital, Bologna, Italy

  • Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey

  • Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

  • Moffitt Cancer Center, Tampa, FL

  • Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

  • Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY

  • Bristol‐Myers Squibb, San Francisco, CA

  • Bristol-Myers Squibb, Summit, NJ

  • Acceleron Pharma, Cambridge, MA

  • Service d'Hematologie Seniors/Hopital Saint-Louis, Universite Paris 7, Paris, France

  • Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

Locations

  • United Kingdom

  • United States

  • Canada

  • Italy

  • Spain

  • Turkey

  • France

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Erythropoietin

  • luspatercept

Outcome

  • N/A

Study Design

  • Placebo Control

  • Multinational

Phase

  • III

Study Id's

  • NCT02631070

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved